Merck & Company Inc (MRK)vsScienture Holdings, Inc. (SCNX)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
SCNX
Scienture Holdings, Inc.
$0.35
-2.69%
HEALTHCARE · Cap: $15.32M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 8105023% more annual revenue ($66.57B vs $821,320). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
SCNX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+61.0%
Fair Value
$1.15
Current Price
$0.35
$0.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Revenue surging 449.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -0.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SCNX
The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SCNX
The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while SCNX is a hypergrowth play — different risk/reward profiles.
SCNX carries more volatility with a beta of 3.98 — expect wider price swings.
SCNX is growing revenue faster at 449.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 33/100). SCNX offers better value entry with a 61.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Scienture Holdings, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Scienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm focused on transforming the treatment landscape for neurological disorders through its advanced drug development pipeline and a seasoned research team. The company is dedicated to addressing significant unmet medical needs, highlighting its potential to enhance patient outcomes while skillfully navigating regulatory complexities. With a strong emphasis on scientific integrity and strategic collaborations, Scienture is well-positioned to leverage growth opportunities in the burgeoning global healthcare market, particularly as the demand for effective neurological therapies continues to rise.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?